Skip to main content
SpringerLink
Log in

Primary Antibiotic Resistance of Helicobacter pylori in China

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background and Aims

Antibiotic resistance is the most important factor leading to the failure of eradication regimens; thus, it is important to obtain regional antibiotic resistance information. This review focuses on the prevalence of Helicobacter pylori primary resistance to clarithromycin, metronidazole, amoxicillin, levofloxacin, tetracycline, and furazolidone in China.

Methods

We searched the PubMed, EMBASE, the China National Knowledge Infrastructure, and Chinese Biomedical databases from the earliest date of each database to October 2016. The search terms included the following: H. pylori, antibiotic (including clarithromycin, metronidazole, amoxicillin, levofloxacin, tetracycline, and furazolidone) resistance with or without China or different regions of China. The data analysis was performed using MedCalc 15.2.2. Each article was weighted according to the number of isolated H. pylori strains. A pooled proportion analysis was performed.

Results

Twenty-three studies (14 studies in English and 9 in Chinese) were included in this review. A total of 6274, 6418, 3921, 5468, 2802, and 275 H. pylori strains were included in this review to evaluate the prevalence of H. pylori primary resistance to clarithromycin, metronidazole, levofloxacin, amoxicillin, tetracycline, and furazolidone, respectively. Overall, the primary resistance rates of clarithromycin, metronidazole, levofloxacin, amoxicillin, tetracycline, and furazolidone were 28.9, 63.8, 28.0, 3.1, 3.9, and 1.7%, respectively.

Conclusions

In China, the prevalence of H. pylori primary resistance to clarithromycin, metronidazole, and levofloxacin was high and increased over time, whereas the resistance rates to amoxicillin, tetracycline, and furazolidone were low and stable over time.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Sipponen P. Natural history of gastritis and its relationship to peptic ulcer disease. Digestion. 1992;51:70–75.

    Article  PubMed  Google Scholar 

  2. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353–1367.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015;148:719–731.e3.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Goni E, Franceschi F. Helicobacter pylori and extragastric diseases. Helicobacter. 2016;21:45–48.

    Article  PubMed  Google Scholar 

  5. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241.

    Google Scholar 

  6. Leja M, Axon A, Brenner H. Epidemiology of Helicobacter pylori infection. Helicobacter. 2016;21:3–7.

    Article  PubMed  Google Scholar 

  7. Goh KL, Chan WK, Shiota S, Yamaoka Y. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter. 2011;16:1–9.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Mentis A, Lehours P, Mégraud F. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter. 2015;20:1–7.

    Article  PubMed  Google Scholar 

  9. Nagy P, Johansson S, Molloy-Bland M. Systematic review of time trends in the prevalence of Helicobacter pylori infection in China and the USA. Gut Pathog. 2016;8:8.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132.

    Article  PubMed  Google Scholar 

  11. Pan KF, Zhang L, Gerhard M, et al. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. Gut. 2016;65:9–18.

    Article  CAS  PubMed  Google Scholar 

  12. Ding Z, Zhao S, Gong S, et al. Prevalence and risk factors of Helicobacter pylori infection in asymptomatic Chinese children: a prospective, cross-sectional, population-based study. Aliment Pharmacol Ther. 2015;42:1019–1026.

    Article  CAS  PubMed  Google Scholar 

  13. Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514–533.

    Article  CAS  PubMed  Google Scholar 

  14. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report. Gut. 2017;66:6–30.

    Article  CAS  PubMed  Google Scholar 

  15. Stone GG, Shortridge D, Flamm RK, et al. Identification of a 23S rRNA gene mutation in clarithromycin-resistant Helicobacter pylori. Helicobacter. 1996;1:227–228.

    Article  CAS  PubMed  Google Scholar 

  16. Mégraud FH. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53:1374–1384.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Kim JM, Kim JS, Kim N, et al. Gene mutations of 23S rRNA associated with clarithromycin resistance in Helicobacter pylori strains isolated from Korean patients. J Microbiol Biotechnol. 2008;18:1584–1589.

    CAS  PubMed  Google Scholar 

  18. Rimbara E, Noguchi N, Kawai T, Sasatsu M. Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. Antimicrob Agents Chemother. 2008;52:3465–3466.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Hao Q, Li Y, Zhang ZJ, Liu Y, Gao H. New mutation points in 23S rRNA gene associated with Helicobacter pylori resistance to clarithromycin in northeast China. World J Gastroenterol. 2004;10:1075–1077.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Zhen-Hua Z, De-Qiang H, Yong X, Lin-Lin L, Nong-Hua L. Characterization of 23S rRNA gene mutation in primary and secondary clarithromycin-resistant Helicobacter pylori strains from East China. Turk J Gastroenterol. 2013;24:5–9.

    Article  PubMed  Google Scholar 

  21. Smiley R, Bailey J, Sethuraman M, Posecion N, Showkat Ali M. Comparative proteomics analysis of sarcosine insoluble outer membrane proteins from clarithromycin resistant and sensitive strains of Helicobacter pylori. J Microbiol. 2013;51:612–618.

    Article  CAS  PubMed  Google Scholar 

  22. Gao W, Cheng H, Hu F, et al. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter. 2010;15:460–466.

    Article  PubMed  Google Scholar 

  23. Zhang YX, Zhou LY, Song ZQ, Zhang JZ, He LH, Ding Y. Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: a prospective serial study. World J Gastroenterol. 2015;21:2786–2792.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Liu Q, Qi D, Kang J, et al. Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 2015;27:221–225.

    Article  CAS  PubMed  Google Scholar 

  25. Bai P, Zhou LY, Xiao XM, Luo Y, Ding Y. Susceptibility of Helicobacter pylori to antibiotics in Chinese patients. J Dig Dis. 2015;16:464–470.

    Article  CAS  PubMed  Google Scholar 

  26. Zhang YX, Zhou LY, Song ZQ, et al. Susceptibility and multiple-factor analysis of Helicobacter pylori derived from gastric mucosa. Chin J Min Inv Surg. 2015;15:577–582. (in Chinese).

    Google Scholar 

  27. Song Z, Zhou L, Zhang J, He L, Bai P, Xue Y. Hybrid therapy as first-line regimen for Helicobacter pylori eradication in populations with high antibiotic resistance rates. Helicobacter. 2016;21:382–388.

    Article  CAS  PubMed  Google Scholar 

  28. Meng X, Liu GF, Wu J, et al. Susceptibility analysis of clinical Helicobacter pylori in Hebei region. Natl Med J China. 2016;96:270–272. (in Chinese).

    CAS  Google Scholar 

  29. Gu Q, Wang H, Gao JP, et al. The investigation on the primary antibiotic resistance of Helicobacter pylori in the central region of Shanghai. Gastroenterologist. 2007;12:609–612. (in Chinese).

    Google Scholar 

  30. Zheng Q, Chen WJ, Lu H, Sun QJ, Xiao SD. Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance. J Dig Dis. 2010;11:313–318.

    Article  PubMed  Google Scholar 

  31. Tan HL, Liu B, Liu TF, Wang YF, Yin DM, Zhou XQ. The research on the antibiotic resistance of Helicobacter pylori in Qingpu area of Shanghai. Chin J Gastroenterol. 2011;16:32–35. (in Chinese).

    Google Scholar 

  32. Liao J, Zheng Q, Liang X, et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter. 2013;18:373–377.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Zhang YM, Hu FJ, Zhao FJ, et al. Susceptibility analyse of Helicobacter pylori and its related resistance gene. Lab Med. 2016;5:412–418.

    Google Scholar 

  34. Zhang W, Chen Q, Liang X, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut. 2015;64:1715–1720.

    Article  CAS  PubMed  Google Scholar 

  35. Sun Q, Liang X, Zheng Q, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010;15:233–238.

    Article  CAS  PubMed  Google Scholar 

  36. Hong J, Shu X, Liu D, et al. Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection: an open-label, randomized, single-centre clinical trial. J Antimicrob Chemother. 2016;71:2280–2285.

    Article  CAS  PubMed  Google Scholar 

  37. Lu L, Huang C, Chang C, Li JJ, Cai DX, Xu ML. Susceptibility analyse of Helicobacter pylori in Meizhou city of Guangdong and treatment strategy. Chin J Med Pharm. 2014;21:2894–2897. (in Chinese).

    CAS  Google Scholar 

  38. Hu GS. Susceptibility analyse of Helicobacter pylori in vitro in Xiamen region. Chin Foreign Med Res. 2013;11:76–78. (in Chinese).

    Google Scholar 

  39. Ruan HL, Mao WH, Chen RL, et al. Susceptibility analyse of Helicobacter pylori in island and urban of Fujian Province. Chin J Dig. 2007;27:198–199. (in Chinese).

    Google Scholar 

  40. Han R, Lu H, Jiang MW, et al. Multicenter study of antibiotic resistance profile of H. pylori and distribution of CYP2C19 gene polymorphism in Rural population of Chongqing, China. Gastroenterol Res Pract. 2016;2016:8547686.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Zhou L, Zhang J, Chen M, et al. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. Am J Gastroenterol. 2014;109:535–541.

    Article  CAS  PubMed  Google Scholar 

  42. Song Z, Zhang J, He L, et al. Prospective multi-region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients. Dig Liver Dis. 2014;46:1077–1081.

    Article  CAS  PubMed  Google Scholar 

  43. Zhou L, Zhang J, Song Z, et al. Tailored versus triple plus bismuth or concomitant therapy as initial Helicobacter pylori treatment: a randomized trial. Helicobacter. 2016;21:91–99.

    Article  CAS  PubMed  Google Scholar 

  44. Goodwin A, Kersulyte D, Sisson G, Veldhuyzen van Zanten SJ, Berg DE, Hoffman PS. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol Microbiol. 1998;28:383–393.

    Article  CAS  PubMed  Google Scholar 

  45. Jenks PJ, Edwards DI. Metronidazole resistance in Helicobacter pylori. Int J Antimicrob Agents. 2002;19:1–7.

    Article  CAS  PubMed  Google Scholar 

  46. Kim SY, Joo YM, Lee HS, et al. Genetic analysis of Helicobacter pylori clinical isolates suggests resistance to metronidazole can occur without the loss of functional rdxA. J Antibiot (Tokyo). 2009;62:43–50.

    Article  CAS  Google Scholar 

  47. Mehrabadi JF, Sirous M, Daryani NE, Eshraghi S, Akbari B, Shirazi MH. Assessing the role of the RND efflux pump in metronidazole resistance of Helicobacter pylori by RT-PCR assay. J Infect Dev Ctries. 2011;5:88–93.

    Article  PubMed  Google Scholar 

  48. Hu YY, Zhou ZF, Nan Q, et al. The investigations on the metronidazole resistance of Helicobacter pylori in three nationalities of Yunnan Province. Chin J Epidermiol. 2004;25:986–988. (in Chinese).

    CAS  Google Scholar 

  49. Cheng H, Hu FL, Zhang GX, et al. Levofloxacin-containing triple therapy as a first-line treatment for Helicobacter pylori: a multiple center, randomized clinical trail. Chin J Med. 2010;90:79–82. (in Chinese).

    Google Scholar 

  50. Tankovic J, Lascols C, Sculo Q, Petit JC, Soussy CJ. Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother. 2003;47:3942–3944.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Rimbara E, Noguchi N, Kawai T, Sasatsu M. Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of gyrA on the level of resistance and identification of a resistance conferring mutation in gyrB. Helicobacter. 2012;17:36–42.

    Article  CAS  PubMed  Google Scholar 

  52. Okamoto T, Yoshiyama H, Nakazawa T, et al. A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. J Antimicrob Chemother. 2002;50:849–856.

    Article  CAS  PubMed  Google Scholar 

  53. Tseng YS, Wu DC, Chang CY, et al. Amoxicillin resistance with beta-lactamase production in Helicobacter pylori. Eur J Clin Invest. 2009;39:807–812.

    Article  CAS  PubMed  Google Scholar 

  54. Rimbara E, Noguchi N, Kawai T, Sasatsu M. Mutations in penicillin-binding proteins 1, 2 and 3 are responsible for amoxicillin resistance in Helicobacter pylori. J Antimicrob Chemother. 2008;61:995–998.

    Article  CAS  PubMed  Google Scholar 

  55. Qureshi NN, Gallaher B, Schiller NL. Evolution of amoxicillin resistance of Helicobacter pylori in vitro: characterization of resistance mechanisms. Microb Drug Resist. 2014;20:509–516.

    Article  CAS  PubMed  Google Scholar 

  56. Gerrits MM, de Zoete MR, Arents NL, Kuipers EJ, Kusters JG. 16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother. 2002;46:2996–3000.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Anoushiravani M, Falsafi T, Niknam V. Proton motive force-dependent efflux of tetracycline in clinical isolates of Helicobacter pylori. J Med Microbiol. 2009;58:1309–1313.

    Article  CAS  PubMed  Google Scholar 

  58. Su Z, Xu H, Zhang C, et al. Mutations in Helicobacter pylori porD and oorD genes may contribute to furazolidone resistance. Croat Med J. 2006;47:410–415.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143–1153.

    Article  CAS  PubMed  Google Scholar 

  60. Graham DY, Dore MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016;14:577–585.

    Article  CAS  PubMed  Google Scholar 

  61. Wang YH, Lv ZF, Zhong Y, Liu DS, Chen SP, Xie Y. The internalization of Helicobacter pylori plays a role in the failure of H. pylori eradication. Helicobacter. 2017. doi:10.1111/hel.12324.

  62. Okamura T, Suga T, Nagaya T, et al. Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: a multi-generational comparison. Helicobacter. 2014;19:214–220.

    Article  CAS  PubMed  Google Scholar 

  63. Lee JW, Kim N, Kim JM, et al. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter. 2013;18:206–214.

    Article  CAS  PubMed  Google Scholar 

  64. Ang TL, Fock KM, Ang D, Kwek AB, Teo EK, Dhamodaran S. The changing profile of Helicobacter pylori antibiotic resistance in Singapore: a 15-year study. Helicobacter. 2016;21:261–265.

    Article  CAS  PubMed  Google Scholar 

  65. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34–42.

    Article  CAS  PubMed  Google Scholar 

  66. Shiota S, Reddy R, Alsarraj A, El-Serag HB, Graham DY. Antibiotic resistance of Helicobacter pylori among male United States veterans. Clin Gastroenterol Hepatol. 2015;13:1616–1624.

    Article  CAS  PubMed  Google Scholar 

  67. Xie Y, Zhu Y, Zhou H, et al. Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection. World J Gastroenterol. 2014;20:11415–11421.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65:870–878.

    Article  PubMed  Google Scholar 

  69. Xie C, Lu NH. Review: clinical management of Helicobacter pylori infection in China. Helicobacter. 2015;20:1–10.

    Article  PubMed  Google Scholar 

  70. Liu WZ, Xie Y, Cheng H, et al. Fourth Chinese National consensus report on the management of Helicobacter pylori infection. J Dig Dis. 2013;14:211–221.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Professor David Y. Graham at Baylor College of Medicine for providing advice regarding this review. This work was supported by the National Natural Science Foundation of China (Nos. 81270479, 81460116, 81470832, and 81670507), the Graduate Innovation Fund of Jiangxi Province (YC2016-B025), Grants from the Jiangxi Province Talent 555 Project, and the National Science and Technology Major Projects for “Major New Drugs Innovation and Development” of China (No. 2011ZX09302-007-03).

Author’s contribution

HY wrote the manuscript; ZY and LNH revised the review.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, 17 YongWaizheng Street, Donghu District, Nanchang, 330006, Jiangxi Province, China

    Yi Hu, Yin Zhu & Nong-hua Lu

Authors
  1. Yi Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yin Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nong-hua Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yin Zhu or Nong-hua Lu.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hu, Y., Zhu, Y. & Lu, Nh. Primary Antibiotic Resistance of Helicobacter pylori in China. Dig Dis Sci 62, 1146–1154 (2017). https://doi.org/10.1007/s10620-017-4536-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-017-4536-8

Keywords

Search

Navigation